A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2011
10/20/2011	WO2011129371A1 GENE GROUP CAPABLE OF ENHANCING ANTI-TUMOR EFFECT OF 5-FU ALONE OR IFN-α/5-FU COMBINATION
10/20/2011	WO2011129095A1 Pyridone derivative having integrase inhibitory activity
10/20/2011	US20110257272 Mixed crystals, method for the production thereof and use thereof in the production of baked goods
10/20/2011	US20110257271 Derivatives of dimethylcurcumin
10/20/2011	US20110257158 Precompacted fast-disintegrating formulations of compounds with a low oral bioavailability
10/20/2011	US20110257142 Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11-beta-yl]benzaldehyde (e)-oxime (asoprisnil)
10/20/2011	US20110257131 Phenylalkyl-imidazole-bisphosphonate compounds
10/20/2011	US20110257100 Inhibitors of Protein Tyrosine Kinase Activity
10/20/2011	US20110257098 Compositions and methods for treating growth hormone deficiency
10/20/2011	US20110257093 Therapies for acute renal failure
10/20/2011	US20110257089 Liquid high-fat protein composition
10/20/2011	US20110257085 Crystal Forms of Saxagliptin and Processes for Preparing Same
10/20/2011	US20110257075 Guanidino acetic acid used as an animal food additive
10/20/2011	US20110256235 Compositions and methods relating to prevention of chemotherapy-induced alopecia
10/20/2011	US20110256226 Opioid agonist formulations with releasable and sequestered antagonist
10/20/2011	US20110256221 Pharmaceutical formulations of olmesartan
10/20/2011	US20110256217 Pulsatile release compositions and methods for enhanced intestinal drug absorption
10/20/2011	US20110256204 Rapid preparation and use of engineered tissue and scaffolds as individual implants
10/20/2011	US20110256202 Immunocompatible amniotic membrane products
10/20/2011	US20110256201 Hydrolyzed hydrogels
10/20/2011	US20110256132 Myostatin binding proteins
10/20/2011	US20110256106 Methods and Compositions for Treating Intervertebral Disc Degeneration
10/20/2011	US20110256068 Contrast media compositions
10/20/2011	US20110256065 Non-Isotopic Detection of Osteoblastic Activity In Vivo Using Modified Bisphosphonates
10/20/2011	US20110256054 Compositions and Methods for the Treatment and Prevention of Lens Fibrotic Diseases
10/19/2011	EP2377891A1 Diagnosis and treatment of cancer using anti-lgr7 antibody
10/19/2011	EP2377851A1 Isoquinoline derivative
10/19/2011	EP2377533A2 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
10/19/2011	EP2376494A1 Dihydropyrimidopyrimidine derivatives
10/19/2011	EP2376493A1 Dihydropyrimidopyrimidine derivative
10/19/2011	EP2375903A1 A method of treating insomnia
10/19/2011	EP2221377B1 Oligonucleotide compositions with enhanced efficiency
10/19/2011	EP1923387B1 Acylguanidine derivative or salt thereof
10/19/2011	EP1762610B1 Truncated dance, dance complex and method of using these
10/19/2011	EP1499321B1 Methods for increasing the therapeutic response to electroconvulsive therapy ("ect")
10/19/2011	EP1482931B1 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
10/19/2011	EP1383793B1 Insulin and igf-1 receptor agonists and antagonists
10/19/2011	EP1372735B1 Conjugate of hydroxyalkyl starch and an active agent
10/19/2011	EP1341524B1 Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
10/19/2011	EP1165132B1 Dry formulation for transcutaneous immunization
10/19/2011	EP1139974B1 Soy depigmenting and skin care compositions
10/19/2011	EP1041982B1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
10/19/2011	DE202011004860U1 Arznei- oder Nahrungsergänzungsmittel zur Behandlung und/oder Prophylaxe von als negativ empfundener Geruchsbelästigung von Stoffwechselprodukten über Mund- und/oder Nasenhöhle und/oder Urin und/oder Stuhl Drugs, or dietary supplements for the treatment and / or prophylaxis of perceived negative odor of metabolites through oral and / or nasal cavity and / or urine and / or stool
10/19/2011	CN1993357B Contrast agents endowed with high relaxivity for use in magnetic resonance imaging (mri) which contain a chelating moiety with polyhydroxylated substituents
10/19/2011	CN1251097B Phthalazines with angiogenesis inhibiting activity
10/19/2011	CN102224252A Novel compound signamycin, method for production thereof, and use thereof
10/19/2011	CN102224142A Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity
10/19/2011	CN102220280A Methods of proliferating stem cells
10/19/2011	CN102219750A N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
10/19/2011	CN102217880A Heat-clearing and heatstroke-preventing health care drug pillow
10/19/2011	CN101696205B 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition
10/19/2011	CN101327200B Glycerol fruit sugar injection and preparation method thereof
10/18/2011	US8039647 2-amino-bicyclo (3.1.0) hexane-2,6-dicarboxylic ester derivative
10/18/2011	US8039508 Obesity therapy; mixture of lipase inhibitor orlistat and sucrose fatty acid ester
10/18/2011	US8039253 Contains erythropoietin, which protectively acts on survival of oligodendrocytes, which form myelin sheath, in cerebrovascular dementia typified by multiple sclerosis and Binswanger disease
10/18/2011	US8039026 Methods for treating skin pigmentation
10/18/2011	US8039011 A temperature change composition including a neurosensory component, e.g., menthol, and a first phase change component having a first phase change temperature between 15-40 degrees C., e.g., hydrocarbon, wax; encapsulated evaporative cooling agent; refreshing; durability; receptivity with other skin item
10/18/2011	US8038996 Composition and method for cancer treatment
10/18/2011	CA2673449C A combination comprising combretastatin and anticancer agents
10/18/2011	CA2598294C Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivative
10/18/2011	CA2579207C Morpholine compound
10/18/2011	CA2494557C Fused heterocyclic isoxazoline derivatives and their use as anti-depressants
10/18/2011	CA2484038C Estrogen receptor modulators
10/18/2011	CA2478813C Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors
10/18/2011	CA2475312C N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
10/18/2011	CA2466499C Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
10/18/2011	CA2462345C Dimeric compounds and their use as anti-viral agents
10/18/2011	CA2443950C Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
10/18/2011	CA2360275C Novel stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas
10/18/2011	CA2337328C Biocompatible polymers, preparation method and compositions containing same
10/13/2011	WO2011126054A1 Physiologically active peptides
10/13/2011	WO2011125916A1 Composition for amelioration of hypoalbuminemia
10/13/2011	WO2011125911A1 Metal complexes and anticancer agents comprising same as active ingredient
10/13/2011	WO2011125838A1 Therapeutic agent or preventive agent for urine collection disorder
10/13/2011	WO2011125619A1 Intestinal protectant
10/13/2011	WO2011125600A1 Method and device for cell activation
10/13/2011	WO2011123890A1 Radioprotector compounds and methods
10/13/2011	WO2011034951A3 Assisted enzyme replacement therapy
10/13/2011	US20110251294 Fast recovery of thixotropy by organogels with low molecular weight gelators
10/13/2011	US20110251280 Stable Aqueous Compositions Comprising Amide-Protected Bioactive Creatine Species and Uses Thereof
10/13/2011	US20110251244 Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient
10/13/2011	US20110251224 Spiro-oxindole compounds and their uses as therapeutic agents
10/13/2011	US20110251171 Heterocyclic compounds and methods of use
10/13/2011	US20110251138 Lipoic acid metabolite conjugate: preparation and their therapeutic effect
10/13/2011	US20110251122 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
10/13/2011	US20110250263 Protein and nucleic acid delivery vehicles, components and mechanisms thereof
10/13/2011	US20110250261 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
10/13/2011	US20110250245 Use of stinging cells/capsules for the delivery of active agents to keratinous substances
10/13/2011	US20110250194 Treatment with Anti-ErbB2 Antibodies
10/13/2011	US20110250189 T cell apoptosis inducer
10/13/2011	US20110250180 Ccn3 peptides and analogs thereof for therapeutic use
10/13/2011	US20110250146 Magnetic nanoparticle and method for imaging t cells
10/13/2011	US20110250137 Radioisotope-labeled lysine and ornithine derivatives, their use and processes for their preparation
10/13/2011	US20110250133 Gastrin releasing peptide compounds
10/13/2011	US20110250132 Lipoic acid metabolite: useful for drug carrier, nanoparticle conjugate, imaging and hyperthermia therapy
10/13/2011	US20110250130 Tnf-alpha binding proteins
10/13/2011	CA2795370A1 Radioprotector compounds and methods
10/13/2011	CA2793951A1 Composition for amelioration of hypoalbuminemia
10/13/2011	CA2793730A1 Therapeutic agent or preventive agent for urine collection disorder
10/12/2011	EP2374884A2 Human miRNAs isolated from mesenchymal stem cells

1 ... 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 ... 1564